BioSyent names new CFO; adds VP corporate development

handshake-partnership-teamwork-520704954-SM.jpg

BioSyent (TSXV:RX) appointed Robert March as VP of finance and CFO, succeeding Alfred D’Souza, who has retired after 12 years of service to the company, but will ensure a smooth transition to Mr. March and continue to act in an advisory capacity to the company on an ongoing basis.

Prior to joining BioSyent, Mr. March accumulated over 15 years of progressive senior management experience in highly-regulated industries in both Canada and the U.S, most recently as CFO and co-COO for Ippolito Group of Companies, a fresh and branded packaged foods supplier and distribution services provider with customers across North America.

René Goehrum, chairman, president and CEO of BioSyent, said Mr. March’s skills and experiences are well suited for the company’s strategic objectives and his values are well aligned with those of BioSyent.

In addition, Joost van der Mark joined the executive management team as VP of corporate development and will be responsible for business development and market access initiatives.

Mr. van der Mark previously was the chief business officer for 3D Signatures. He also has held progressive positions in clinical research, sales, marketing, market access, strategy and business development at Bayer, Sanofi, Nycomend and Knight Therapeutics.

Mr. Goehrum said Mr. van der Mark brings extensive industry experience and knowledge to BioSyent and will be “instrumental in our efforts to continue to expand our product portfolio.”

Jennifer Poland